Responsive Neurostimulation for Epilepsy | Mass General Brigham
•February 25, 2026
0
Why It Matters
RNS provides a life‑changing, non‑destructive option for drug‑resistant epilepsy, lowering seizure frequency and medication dependence while leveraging remote data analytics for individualized treatment.
Key Takeaways
- •RNS approved 2014 for medication‑resistant epilepsy in the United States
- •Device detects seizure activity and delivers abortive electrical pulses
- •~75% of patients achieve ≥75% seizure reduction over a multi‑year follow‑up
- •Leads implanted in seizure foci; neurostimulator sits under scalp
- •Patients upload data to secure cloud for clinician‑driven device tuning
Summary
The video introduces responsive neurostimulation (RNS), a minimally invasive neuromodulation therapy approved by the FDA in 2014 for adults with medication‑resistant epilepsy. Unlike traditional drugs or resective surgery, RNS functions as a brain‑pacemaker, continuously monitoring electrical activity and delivering targeted pulses to abort seizures before they fully develop.
Clinical data highlighted in the presentation show that roughly three‑quarters of implanted patients experience at least a 75% reduction in seizure frequency, with many able to taper or discontinue anti‑epileptic drugs. The system consists of two thin leads placed in the seizure‑generating zones of the cortex, connected to a key‑fob‑sized neurostimulator implanted beneath the scalp. Post‑procedure recovery is rapid, typically allowing discharge within 48 hours and a swift return to daily activities.
The narrative emphasizes the collaborative care model at Mass General Brigham Neuroscience Institute, involving neurosurgeons, neurologists, and nurse navigators. Patients regularly upload encrypted brain‑signal data to a secure cloud, enabling clinicians to fine‑tune stimulation parameters remotely. The analogy of a pacemaker for the brain underscores the device’s real‑time, adaptive nature.
For the broader epilepsy community, RNS offers a viable alternative when medications fail, reducing seizure burden and medication side effects while preserving brain tissue. Its cloud‑based monitoring platform also exemplifies the shift toward personalized, data‑driven neurological care, potentially expanding access to advanced therapies across health systems.
Original Description
Responsive neurostimulation (RNS) is a small device that is implanted into the brain to stop seizures before they occur. Similar to a pacemaker, an RNS device is programmed to recognize seizures before they happen and prevent them.
Learn more about the Mass General Brigham Neuroscience Institute: https://www.massgeneralbrigham.org/en/about/neuroscience-institute
About Mass General Brigham:
Mass General Brigham combines the strength of two world-class academic medical centers, five nationally ranked specialty hospitals, 11 community hospitals, and dozens of health centers. Our doctors and researchers accelerate medical breakthroughs and drive innovations in patient care. They are leaders in medical education, serving as Harvard Medical School faculty and training the next generation of physicians. Mass General Brigham’s mission is to deliver the best, affordable health care to patients everywhere. Together, we transform the health of our communities and beyond.
Find us on social:
0
Comments
Want to join the conversation?
Loading comments...